Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
2.170
+0.080 (3.83%)
At close: Jul 22, 2026, 4:00 PM EDT
2.170
0.00 (0.00%)
After-hours: Jul 22, 2026, 8:00 PM EDT
Serina Therapeutics Employees
Serina Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 3 or 23.08% compared to the previous year.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
$8,125
Profits / Employee
-$1,347,375
Market Cap
32.54M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 3 | 23.08% | 16 | 0 |
| Dec 31, 2024 | 13 | 2 | 18.18% | 12 | 1 |
| Dec 31, 2023 | 11 | - | - | 9 | 2 |
| Sep 30, 2023 | 9 | - | - | 5 | 4 |
| Jun 30, 2023 | 9 | - | - | 5 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Kyntra Bio | 34 |
| Veru Inc. | 20 |
| ABVC BioPharma | 19 |
| BriaCell Therapeutics | 16 |
| Lantern Pharma | 16 |
| Actuate Therapeutics | 12 |
| VYNE Therapeutics | 10 |
SER News
- 4 hours ago - Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board - TheFly
- 13 days ago - Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252 - TheFly
- 13 days ago - Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 21 days ago - Serina Therapeutics initiated with a Buy at BTIG - TheFly
- 22 days ago - Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Serina Therapeutics files to sell 16.45M shares of common stock for holders - TheFly
- 2 months ago - Serina Therapeutics Registration statement: Registration filing - Filings